Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
HOUSTON , Aug. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates t
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
08:30am, Thursday, 01'st Aug 2024
Based on an encouraging discussion in the End of Phase 1B/2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible a
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
08:30am, Wednesday, 10'th Jul 2024
HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
08:00am, Friday, 14'th Jun 2024
– 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and increasing (n=9) – In 2nd line subject
Moleculin to Present at the Virtual Investor Pitch Conference
09:00am, Wednesday, 12'th Jun 2024
Live video webcast on Tuesday, June 18 th at 3:00 PM ET HOUSTON , June 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical
Moleculin to Participate in the Virtual Investor Lunch Break Series
08:55am, Wednesday, 05'th Jun 2024
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12 th at 12:00 PM ET HOUSTON , June 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Molec
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
08:32am, Thursday, 16'th May 2024
HOUSTON , May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
08:38am, Wednesday, 15'th May 2024
– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Trial combines WP1066 and radiation, which demonstrated both significant therap
Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript
11:44am, Monday, 13'th May 2024
Moleculin Biotech, Inc. [MBRX] Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO Jonathan Foster - EVP and CFO Paul Waymack - Senior CMO Jen
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:30am, Monday, 13'th May 2024
– Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subject
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
08:30am, Thursday, 09'th May 2024
Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an acc
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
08:45am, Wednesday, 08'th May 2024
HOUSTON , May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
08:55am, Tuesday, 07'th May 2024
Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line,
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
09:00am, Thursday, 02'nd May 2024
Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Com
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
08:50am, Wednesday, 01'st May 2024
– Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Mole
